A Phase 1/2, Multicenter, Open-label Study of FT 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation.

Forma Therapeutics, Inc.0 个研究点目标入组 335 人开始时间: 2017年12月19日最近更新: 2024年4月2日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Forma Therapeutics, Inc.
入组人数: 335

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Pathologically proven AML (except acute promyelocytic leukemia with the t(15;17) translocation) or intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or
•Revised International Prognostic Scoring System (IPSS-R) harboring IDH1-R132 mutations, and one of the following based on enrollment stage or treatment cohort:
•a. Single Agent Phase 1 Cohorts including Dose-Escalation/Dose-Expansion: AML/MDS either R/R to standard therapy, or for whom standard treatments are contraindicated
•b. Combination (FT-2102 + azacitidine) Phase 1 Dose-Escalation/ Dose-Expansion (patients must meet one of the following):
•i. Patients with AML that is either R/R to standard therapy, or for whom standard treatments are contraindicated
•ii. Patients that have MDS that is either R/R to standard therapy, or are treatment-naïve, who are eligible for azacitidine therapy
•c. Combination (FT-2102 + Cytarabine) Phase 1 Dose-Escalation/Dose- Expansion Cohort: Patients = 60 years with treatment-naïve AML for whom standard treatments are contraindicated
•d. Phase 2 Cohort 1 (Single Agent) only: AML R/R to standard therapy
•e. Phase 2 Cohort 2 (Single Agent) only: AML in morphologic CR/CRi after prior therapy (+/- HSCT) with residual IDH1-R132 mutation (= 0.01%) detected in the bone marrow
•f. Phase 2 Cohort 3 (Single Agent) only: R/R AML/MDS that have been previously treated with FT-2102 AND for whom standard treatments are contraindicated
•g. Phase 2 Cohort 4 (FT-2102 + Azacitidine) only: Patients < 60 years old with R/R AML/MDS with no prior hypomethylating agent therapy AND no prior IDH-1 inhibitor therapy
•h. Phase 2 Cohort 5 (FT-2102 + Azacitidine) only: R/R AML/MDS that have inadequately responded to or have progressed on prior treatment with a hypomethylating agent
•i. Phase 2 Cohort 6 (FT-2102 + Azacitidine) only: R/R AML/MDS that have been previously treated with a single agent FT-2102 as their last therapy prior to study enrollment
•j. Phase 2 Cohort 7 (Single Agent) only: Treatment naïve AML patients for whom standard treatments are contraindicated
•k. Phase 2 Cohort 8 (FT-2102 + Azacitidine) only: Treatment naïve AML patients who are candidates for azacitidine first line treatment.
•? Note for Phase 2 Cohort 7 and Phase 2 Cohort 8: Treatment naïve is defined as no prior treatment for AML. Patients may have received a prior treatment for another hematologic malignancy.
•2. Patients must have documented IDH1-R132 gene-mutated disease as
•evaluated by the site
•3. Patients = 18 years old
•4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (see Appendix 3)
•5. Signed informed consent prior to beginning study and undergoing
•6. No prior solid organ allograft
•7. Acceptable liver function:
•a. Bilirubin = 2 times upper limit of normal (ULN) (= 3 times ULN in
•patients with Gilbert Syndrome)
•b. Aspartate transaminase (AST, also referred to as SGOT), alanine
•transaminase (ALT, also referred to as SGPT) and alkaline phosphatase
•(ALP) = 3 times ULN
•8. Acceptable renal function:
•a. Serum creatinine = 1.5 times ULN or calculated creatinine clearance =
•50 mL/min (Cockcroft and Gault 1976)
•9. Recovery from the non-hematologic toxic effects of prior treatment to Grade = 1, or baseline value according to NCI CTCAE classification (excluding infertility, alopecia, or Grade 1 neuropathy)
•10. Baseline QTcF = 450 msec (average of the QTcF values of screening triplicate ECGs) Note: This criterion does not apply to pa

排除标准

•1. Phase 1 single agent dose-escalation/dose expansion cohorts and Phase 2 Cohorts 1, 4, 5, 7 and 8 only: Patients who have been treated with an IDH1 targeted therapy
•2. Phase 2 Single Agent Cohorts 1-3 and 7 only: Patients with IDH2 mutation detection at baseline or history of IDH2m inhibitor treatment
•3. History of prior malignancy unless disease-free for = 12 months or considered surgically cured; patients with nonmelanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis
•(including concomitant diagnoses)
•4. Patients with symptomatic central nervous system (CNS) metastases or other tumor location (such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture, etc.)
•necessitating an urgent therapeutic intervention, palliative care, surgery or radiation therapy
•5. Patients with previous allogeneic HSCT if they meet any of the following criteria: < 100 days from time of HSCT; active acute or chronic graft vs. host disease (GvHD); or receiving immunosuppressive therapy as
•treatment or prophylaxis against GvHD
•Note: Doses < 20 mg methylprednisolone (or its equivalent) daily are not an exclusion criterion.
•6. Treatment with radiation therapy, major surgery (requiring general anesthesia) within one month prior to study drug dosing
•7. Treatment with chemotherapy or small molecule anticancer therapeutic within five halflives of the agent or within 21 days if the half-life is unknown. Patients re-enrolling in Cohort 6 after relapse/progression on Cohort 1 are exempt from this washout requirement (i.e. can continue FT-2102 treatment until re-enrollment)
•8. Treatment with an anticancer therapeutic antibody less than four weeks before first dose of study drug
•9. Treatment with other experimental therapies or participation in another clinical trial within a period of time that is less than the cycle length or within 21 days prior to starting study drug, whichever is shorter
•10. Patients unable to swallow oral medications, or patients with gastrointestinal conditions (e.g., malabsorption, resection, etc.) deemed by the Investigator to jeopardize intestinal absorption
•11. Congestive heart failure (New York Heart Association Class III or IV) or unstable angina pectoris; previous history of myocardial infarction within one year prior to study entry, uncontrolled hypertension, or uncontrolled arrhythmias (see Appendix 5)
•12. Patients with a family history of QT prolongation
•13. Concomitant medication(s) known to cause Torsades de Pointes (TdP) initiated less than the duration required to reach steady-state plasma concentration (approximately five half-lives) before first dose of
•study drug (see Appendix 5) (medications used as needed [PRN] (e.g. Zofran) are exempt)
•14. Concurrent treatment with chronic corticosteroids except if chronic treatment with < 20 mg of methylprednisolone daily or equivalent (pulse steroids for treatment or prophylaxis are allowed [e.g., for transfusion or medication reactions])
•15. Known HIV positivity
•16. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy (prophylactic systemic antimicrobials permitted)
•17. Uncontrolled disease-related metabolic disorder (e.g., hypercalcemia)
•18. Pregnant or nursing women or women of childbearing potential not using adequate contraception; male patients not using adequate contraception
•Note: Women of childbearing potential (see Section 5.6) and men must
•agree to use highly ef

研究者

发起方

Forma Therapeutics, Inc.

相似试验

进行中（未招募）

1 期

EUCTR2017-001051-32-ITFORMA THERAPEUTICS, INC.529

进行中（未招募）

1 期

Study to evaluate FT-2102 as a single agent or in combination with Azacitidine or Cytarabine in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome.Relapsed/refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2017-001051-32-GBForma Therapeutics, Inc.529

招募中

2 期

A phase 2 multicenter, open-labeled study of efficacy and safety of Deferasirox GPO in thalassemia patients with iron overloadtransfusion dependent thalassemia (TDT) and non-transfusion dependent thalassemia (NTDT) patients who have iron overloadthalassemia, iron overload

TCTR20240601004The Government Pharmaceutical Organization (GPO)160

进行中（未招募）

1 期

A Phase 1/2 Open-label, Multi-center Study of the Safety and Effectiveness of Increasing Doses of IMCgp100 in Patients with Advanced Uveal MelanomaAdvanced Uveal MelanomaMedDRA version: 20.0Level: PTClassification code 10061252Term: Intraocular melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-004222-34-GBImmunocore Limited150

进行中（未招募）

1 期

A Phase I/II Open-label, Multi-center Study of the Safety and Effectiveness of Increasing Doses of IMCgp100 in Patients with Advanced Uveal MelanomaAdvanced Uveal MelanomaMedDRA version: 21.0Level: PTClassification code 10061252Term: Intraocular melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-004222-34-DEImmunocore Limited150